Please login to the form below

Not currently logged in
Email:
Password:

Nabriva Therapeutics names Elyse Seltzer as CMO

She joins from GlaxoSmithKline

Clinical stage biopharma firm Nabriva Therapeutics has appointed Elyse Seltzer as chief medical officer.

The company is engaged on the research and development on novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class of antibiotics.

In her new role, Seltzer will supervise medical and regulatory aspects of clinical development and medical affairs, contributing to the company's clinical development strategy.

Commenting on her appointment, Seltzer said: “I am thrilled to join Nabriva. I am excited to have the opportunity to advance a novel class of antibacterials, particularly given the current and evolving challenges around resistance to currently available antibiotics. 

"I look forward to working with the highly experienced clinical team to fulfil this goal."

Seltzer joins Nabriva from GSK, where she was VP of global clinical sciences and operations. Prior to this, Seltzer was CMO at Tengion, a regenerative medicine company.

Dr Colin Broom, CEO of Nabriva, added: “We are very pleased to welcome Elyse to Nabriva. Her extensive experience in the anti-infective therapeutic area, and in leading international clinical development programs will enable us to efficiently advance our lead product, lefamulin, into late stage development for the treatment of CABP.”

Seltzer assumes the role from Dr William Prince, who will take up the position of senior VP of clinical science.

27th May 2015

From: Research

Share

Tags

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Wisepress

Wisepress is a medical bookseller promoting and selling books worldwide, both online and via the 200 European medical conferences that...

Latest intelligence

Pandemic preparedness
The pandemic preparedness paradox
Why our efficient ‘just in time’ mentality must be replaced with a resilient ‘just in case’ activity...
Emre Vural
Sourcing R&D innovation: why pharma companies need to evolve their business models
Recent years have seen a significant shift in drug development to specialty areas...
2020 - a year to remember or forget?
2020 and the Covid pandemic brought immense challenges, and the need for change felt like it happened overnight. What have we learned and what does the future of agency working...

Infographics